Fan et al. reported that Lazertinib, the recently approved EGFR TKI, specifically potentiated the efficacy of the MDR transporters substrates, mitoxantrone and topotecan in the mitoxantrone-resistant ABCG2-overexpressing colon carcinoma cell line S1-M1-80 but not in the parental sensitive colon carcinoma S1 (Fan et al., 2022). This evidence concerns the gene EGFR and colon carcinoma.